Thermo Fisher Scientific and Fujirebio agree biomarker alliance

Thermo Fisher Scientific is teaming up with Fujirebio to make the biomarker assay Procalcitonin (PCT) more widely distributed.

Through this agreement, the assay is set to become available on the Lumipulse family of laboratory instruments via chemiluminescent enzyme immunoassay technology, for use in the detection of sepsis.

Initially, this partnership will focus on the Japanese market – where Lumipulse has a significant presence in hospitals and clinical reference labs – but will later be extended to other countries worldwide.

The PCT assay is already available on several different laboratory instruments from strategic international license partners and has become the gold standard for the early detection of sepsis in critically ill patients in Europe.

Marc Tremblay, president of Thermo Fisher Scientific's clinical diagnostics business, said: "This agreement with Fujirebio ensures that PCT testing will be available to a much broader patient base, helping to improve patient outcomes."

Earlier this month, the business announced the appointment of Dr Klaus Lindpaintner and Dr Edison Liu as the newest members of its scientific advisory board, a move that will bolster its expertise.